Patent intelligence · US
US 12171822
Infectious plasmodium sporozoites grown in vitro
Infectious plasmodium sporozoites grown in vitro
Patent details — US 12171822
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 24, 2024
- Expiration
- Dec 19, 2044
- Applicant
- Sanaria Inc.
- Claims
- 7
- CPC classes
- A61K, A61K2039/52, A61K2039/522, A61K39/015
Quick answer
US 12171822 (Infectious plasmodium sporozoites grown in vitro) is held by Sanaria Inc.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sanaria Inc.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K2039/52, A61K2039/522, A61K39/015, A61P, A61P33/12
More from Sanaria Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12246059
Stable hybrid FC fusion G-CSF formulation
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12129288
Polynucleotides heterodimers of soluble interferon receptors and uses thereof
granted -
US 12077543
P2X3 and/or P2X2/3 compounds and methods
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted
Frequently asked questions
What is US patent 12171822?
US 12171822 (Infectious plasmodium sporozoites grown in vitro) is held by Sanaria Inc.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12171822?
Sanaria Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.
When does US 12171822 expire?
Our index shows an expiration date of Dec 19, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.